Regulatory FDA renews criticism of trial sponsors over transparency PharmaphorumThe FDA has launched a drive to get clinical trial sponsors to disclose the results of studies - even if they are negative.RegulatoryRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 UpdateNext: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
